Liang Wang, MD, PhD
Xu Xin

ACADEMIC CONTACT INFORMATION:

Chief Physician of Guangzhou First People’s hospital.
Visiting Scholar of Mount Sinai Medical College and Hospital, Doctor of Medicine.
Email Address:404163425@qq.com
Tel:00852-020-81048559

EDUCATION

1998/07-2003/06, Department of Clinical Medicine, Sun Yat-sen Medical University, undergraduate
2006/09-2010/06, Master, Department of Clinical Medicine, Guangzhou Medical University
From 2019/08 to now, Ph.D., First Clinical Medical College, Jinan University

EXPERIENCE/SERVICE

2003/7-2012/6,Department of Hematology and Oncology, Department of Geriatrics, Guangzhou First People's Hospital, Resident
2012/7-2015/6, Department of Hematology and Oncology, Department of Geriatrics, Guangzhou First People's Hospital, Attending
2015/7-2017/12, Department of Hematology and Oncology, Department of Geriatrics, Guangzhou First People's Hospital, Vice Chief Physician
From December 2017 to now, Department of Hematology and Oncology, Department of Geriatrics, Guangzhou First People's Hospital, Chief Physician.

HONORS AND AWARDS

Young Professionals in Health System of Guangdong Province (2012)
Guangzhou Health System Annual Assessment Award (2006)
Excellent Party Members of Guangzhou First People's Hospital (2010, 2011)
National Champion of the "Energy Cup" Young Physicians' Academic Speech Competition of the Chinese Society of Geriatrics (2015)

RESEARCH

1. Guangdong Medical Science and Technology Research Foundation Project, 2017102610542590, CYLD Phosphorylation Regulating the Apoptosis of DLBCL Tumor Cells, 2018/7-2020/7, under researching.
2. Guangdong Provincial Science and Technology Project, 2013 B021800040, Th17 Cell Adherent Immunotherapy on DLBCL Tumor Microenvironment and Its Mechanisms, 2014/10-2017/09, completed.
3. Guangzhou Medical and Health Science and Technology Project, 2012A011010004, DLBCL patients received rituximab treatment Th17 cell changes and its correlation with the efficacy of research, 2012/01-2013/12, completed.

REPRESENTATIVE PAPERS

(1)Xin Xu, Matko Kalac, Michael Markson, Mark Chan, Joshua D. Brody, Govind Bhagat, Rosalind L. Ang,Diana Legarda1, Scott J. Justus1, Feng Liu2, Qingshan Li, Huabao Xiong and Adrian T*. TingReversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL).Cell Death and Disease (2020) 11:94. https://doi.org/10.1038/s41419-020-2294-6.
(2) Xin Xu, Matko Kalac, Michael Markson, Joshua Brody, Govind Bhagat, Feng Liu, Qingshan Li, and Adrian Ting. Constitutive Phosphorylation of CYLD Promotes ATLL Survival By Inhibiting RIPK1-Dependent Cell Death. 60th ASH Annual Meeting and Exposition. Blood 2018, San Diego, USA,2018.12.01-12.04. Blood.(2018 )132 (Supplement_1):1581. doi: https: //doi.org/10.1182/ blood -2018-99-117397.
(3)Xin Xu, Zhigang Zhu, Feng Liu , Weijie Zhong,Huabao Xiong, Tiefeng Feng, and Qingshan Li.BTK inhibitors induce ABC-DLBCL cell apoptosis by inhibiting CYLD phosphorylation. 61th ASH Annual Meeting and Exposition. Blood 2019,Orlando, USA,2019.12.06-12.09. Blood (2019) 134 (Supplement_1): 5046.https:// doi.org/ 10.1182/blood-2019-126763.